The Breath-2 Trial

February 7, 2025 updated by: Martijn Boon, Leiden University Medical Center

Recovery of Carotid Body Function After Full Recovery Neuromuscular Block

This is a randomized, cross over, experimental trial in which carotid body function will be evaluated in 35 healthy subjects during partial muscle relaxation and after recovery from muscle relaxation

Study Overview

Status

Completed

Study Type

Interventional

Enrollment (Actual)

35

Phase

  • Phase 4

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Zuid Holland
      • Leiden, Zuid Holland, Netherlands, 2333ZA
        • Leiden Medical University

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

Yes

Description

Inclusion Criteria:

* age > 18 years

Exclusion Criteria:

  • BMI index > 30 kg/m2
  • Known or suspected neuromuscular disorders impairing neuromuscular function;
  • Allergies to muscle relaxants, anesthetics or narcotics;
  • A (family) history of malignant hyperthermia or any other muscle disease;
  • Any neurological or psychiatric illness (including a history of anxiety).
  • ASA class 3 or higher
  • Gastro-oesophageal regurgitation

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Basic Science
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Double

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Other: spontaneous recovery
Spontaneous recovery
Rocuronium will be used to induce partial paralysis
Other: reversal with sugammadex 2 mg/kg
Rocuronium will be used to induce partial paralysis
Sugamamdex will be used to reverse muscle relaxation
Other: reversal with sugammadex 4 mg/kg
Rocuronium will be used to induce partial paralysis
Sugamamdex will be used to reverse muscle relaxation

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Carotid body function after full recovery of neuromuscular block
Time Frame: 40 minutes after full recovery of neuromuscular block
Carotid body function will be determined by measuring acute hypoxic ventilatory response
40 minutes after full recovery of neuromuscular block

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Carotid body function at symptomatic neuromuscular block
Time Frame: 5 minutes after stable partial neuromuscular block
Carotid body function will be determined by measuring acute hypoxic ventilatory response
5 minutes after stable partial neuromuscular block
Carotid body function at full recovery of NMB symptoms
Time Frame: 0 minutes after full recovery of neuromuscular block symptoms
Carotid body function will be determined by measuring acute hypoxic ventilatory response
0 minutes after full recovery of neuromuscular block symptoms
Carotid body function after full recovery of neuromuscular block
Time Frame: 20 minutes after full recovery of neuromuscular block symptoms
Carotid body function will be determined by measuring acute hypoxic ventilatory response
20 minutes after full recovery of neuromuscular block symptoms
Carotid body function after full recovery of neuromuscular block
Time Frame: 40 minutes after full recovery of neuromuscular block symptoms
Carotid body function will be determined by measuring acute hypoxic ventilatory response
40 minutes after full recovery of neuromuscular block symptoms

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

August 15, 2022

Primary Completion (Actual)

November 1, 2022

Study Completion (Actual)

April 1, 2023

Study Registration Dates

First Submitted

November 9, 2021

First Submitted That Met QC Criteria

December 7, 2021

First Posted (Actual)

December 8, 2021

Study Record Updates

Last Update Posted (Actual)

March 25, 2025

Last Update Submitted That Met QC Criteria

February 7, 2025

Last Verified

October 1, 2024

More Information

Terms related to this study

Other Study ID Numbers

  • P21.083

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Peripheral Chemosensitivity

Clinical Trials on Muscle relaxation

Subscribe